JPWO2020178638A5 - - Google Patents

Download PDF

Info

Publication number
JPWO2020178638A5
JPWO2020178638A5 JP2021552586A JP2021552586A JPWO2020178638A5 JP WO2020178638 A5 JPWO2020178638 A5 JP WO2020178638A5 JP 2021552586 A JP2021552586 A JP 2021552586A JP 2021552586 A JP2021552586 A JP 2021552586A JP WO2020178638 A5 JPWO2020178638 A5 JP WO2020178638A5
Authority
JP
Japan
Prior art keywords
composition
patient
stage
antibody
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021552586A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022522889A (ja
JP7619953B2 (ja
JP2022522889A5 (https=
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2020/000186 external-priority patent/WO2020178638A1/en
Publication of JP2022522889A publication Critical patent/JP2022522889A/ja
Publication of JPWO2020178638A5 publication Critical patent/JPWO2020178638A5/ja
Publication of JP2022522889A5 publication Critical patent/JP2022522889A5/ja
Priority to JP2025003299A priority Critical patent/JP2025063135A/ja
Application granted granted Critical
Publication of JP7619953B2 publication Critical patent/JP7619953B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021552586A 2019-03-05 2020-03-05 Alアミロイドーシスを処置する方法 Active JP7619953B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025003299A JP2025063135A (ja) 2019-03-05 2025-01-09 Alアミロイドーシスを処置する方法

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962814252P 2019-03-05 2019-03-05
US62/814,252 2019-03-05
US201962942722P 2019-12-02 2019-12-02
US62/942,722 2019-12-02
PCT/IB2020/000186 WO2020178638A1 (en) 2019-03-05 2020-03-05 Methods of treating al amyloidosis

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025003299A Division JP2025063135A (ja) 2019-03-05 2025-01-09 Alアミロイドーシスを処置する方法

Publications (4)

Publication Number Publication Date
JP2022522889A JP2022522889A (ja) 2022-04-20
JPWO2020178638A5 true JPWO2020178638A5 (https=) 2023-03-13
JP2022522889A5 JP2022522889A5 (https=) 2023-03-13
JP7619953B2 JP7619953B2 (ja) 2025-01-22

Family

ID=70476256

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021552586A Active JP7619953B2 (ja) 2019-03-05 2020-03-05 Alアミロイドーシスを処置する方法
JP2025003299A Pending JP2025063135A (ja) 2019-03-05 2025-01-09 Alアミロイドーシスを処置する方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025003299A Pending JP2025063135A (ja) 2019-03-05 2025-01-09 Alアミロイドーシスを処置する方法

Country Status (17)

Country Link
US (3) US11692024B2 (https=)
EP (2) EP3934689B1 (https=)
JP (2) JP7619953B2 (https=)
KR (1) KR20220019656A (https=)
CN (1) CN113811332A (https=)
AU (1) AU2020231081A1 (https=)
BR (1) BR112021017550A2 (https=)
CA (1) CA3132780A1 (https=)
CL (1) CL2021002318A1 (https=)
FR (1) FR3111560B1 (https=)
IL (1) IL286040A (https=)
JO (1) JOP20210245A1 (https=)
MA (1) MA55209A (https=)
MX (1) MX2021010665A (https=)
PH (1) PH12021552135A1 (https=)
SG (1) SG11202109645QA (https=)
WO (1) WO2020178638A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PH12021552135A1 (en) * 2019-03-05 2022-08-31 Prothena Biosciences Ltd Methods of treating al amyloidosis
AU2021339851A1 (en) * 2020-09-14 2023-04-13 Caelum Biosciences, Inc. Method of treating amyloidosis
TW202332465A (zh) * 2021-01-29 2023-08-16 愛爾蘭商普羅希那生物科學有限公司 治療al類澱粉變性症之方法
US20250345418A1 (en) * 2022-01-11 2025-11-13 Prothena Biosciences Limited Methods of treating al amyloidosis
AR132344A1 (es) * 2023-04-10 2025-06-18 Medimmune Llc Optimización de los dominios de unión al antígeno cd3
TW202547553A (zh) * 2024-02-06 2025-12-16 愛爾蘭商普羅希那生物科學有限公司 治療al類澱粉變性症之方法

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030147882A1 (en) 1998-05-21 2003-08-07 Alan Solomon Methods for amyloid removal using anti-amyloid antibodies
PT1355919E (pt) 2000-12-12 2011-03-02 Medimmune Llc Moléculas com semivida longa, composições que as contêm e suas utilizações
US8263746B2 (en) 2004-02-06 2012-09-11 Morphosys Ag Anti-CD38 human antibodies and uses thereof
EP2567976B1 (en) 2005-03-23 2017-07-19 Genmab A/S Antibodies against CD38 for treatment of multiple myeloma
DK2237803T3 (en) 2007-12-28 2015-10-05 Prothena Biosciences Ltd Treatment and prophylaxis of amyloidosis
DK2580243T3 (da) 2010-06-09 2020-01-13 Genmab As Antibodies against human cd38
SG10201604104PA (en) 2011-10-25 2016-07-28 Prothena Therapeutics Ltd Antibody formulations and methods
AU2012328524B2 (en) 2011-10-28 2017-05-18 Excelse Bio, Inc. Protein formulations containing amino acids
US10213506B2 (en) 2014-08-26 2019-02-26 University Of Tennessee Research Foundation Targeting immunotherapy for amyloidosis
MX389805B (es) 2015-05-20 2025-03-11 Janssen Biotech Inc Anticuerpos anti-cd38 para el tratamiento de amiloidosis de cadena ligera y otras enfermedades malignas hematológicas positivas para cd38.
DK3827845T3 (da) 2015-11-03 2022-05-23 Janssen Biotech Inc Subkutane formuleringer af anti-cd38-antistoffer og anvendelser deraf
WO2018005967A1 (en) 2016-06-30 2018-01-04 Prothena Therapeutics Limited Compositions for treating amyloidosis
US11382974B2 (en) * 2017-08-01 2022-07-12 The Trustees Of Columbia University In The City Of New York Methods and compositions for treatment of amyloid deposition diseases
US12018069B2 (en) 2018-06-28 2024-06-25 The Trustees Of Columbia University In The City Of New York Methods and compositions for imaging amyloid deposits
AU2019429147B2 (en) 2019-02-12 2024-11-14 Prothena Biosciences Limited Treatment of AL amyloidosis with the combination of monoclonal antibodies against immunoglobulin light chains and the CD38 cell membrane molecule on antibody-producing and other immune cells
PH12021552135A1 (en) * 2019-03-05 2022-08-31 Prothena Biosciences Ltd Methods of treating al amyloidosis
TW202332465A (zh) 2021-01-29 2023-08-16 愛爾蘭商普羅希那生物科學有限公司 治療al類澱粉變性症之方法

Similar Documents

Publication Publication Date Title
JP7575526B2 (ja) Il-4r阻害剤の投与によるアレルギー処置方法およびアレルゲン特異的免疫療法の向上方法
JP7836754B2 (ja) Il-4rアンタゴニストを投与することによりアレルギーを治療しアレルゲン特異的免疫療法を増強するための方法
KR102196009B1 (ko) 항체 제형 및 방법
BRPI0615745A2 (pt) formulação de anticorpo anti-cd3
RU2016103079A (ru) Составы антител и способы
JP2021526534A5 (https=)
JPH08506091A (ja) 造血幹細胞の末梢化
JPWO2020178638A5 (https=)
CN119486744A (zh) 艾萨妥昔单抗联合其他药物用于治疗多发性骨髓瘤的用途
JP3973360B2 (ja) 関節リウマチまたは皮膚疾患の処置に使用するためのcd25結合分子
US20260070995A1 (en) Methods for treating bullous pemphigoid by administering an il-4r antagonist
JPWO2022162625A5 (https=)
Stevenson The prospects for treating cancer with antibody
WO1994023747A1 (de) Arzneimittel, das antikörper enthält, zur behandlung von t-zell spezifischen immunreaktionen und t-zell-leukämien
WO2025124481A1 (zh) Tfpi抗体用于治疗血友病
JPWO2020167376A5 (https=)
JPWO2023036745A5 (https=)
WO2024112935A1 (en) Methods for improving bone growth by administering an il-4r antagonist
RU2021135507A (ru) Антитела к cd40 для применения в лечении t1dm и инсулита
JPWO2021118999A5 (https=)
HK1216898B (en) Methods for enhancing allergen-specific immunotherapy by administering an il-4r inhibitor
EP0765171A1 (en) Treatment of autoimmune and inflammatory disorders